Berjame, Angelita R.

HRN: 17-64-79  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/25/2023
CEFTAZIDIME 1GM (VIAL)
09/25/2023
10/01/2023
IV
1g
Q8
Infected Wound
Waiting Final Action 
09/25/2023
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
09/25/2023
10/01/2023
IV
4.5g
Q6
Sepsis
Waiting Final Action 
09/25/2023
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
09/25/2023
10/01/2023
IV
4.5g
Q6
Sepsis
Waiting Final Action 
10/03/2023
MUPIROCIN 2%, 15G (TUBE)
10/03/2023
10/09/2023
TOPICAL
Apply On Affected Areas
Bid
Infected Wound
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

 Indication:

              

 Type of Infection:

                             

           

 Compliance to guidelines:



 Initial appropriateness:



 If inappropriate:

           

 Final appropriateness:



 If inappropriate:

              

 Overall appropriateness: